These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 21878529)

  • 41. The critical DNA flanking sequences of a CpG oligodeoxynucleotide, but not the 6 base CpG motif, can be replaced with RNA without quantitative or qualitative changes in Toll-like receptor 9-mediated activity.
    Sen G; Flora M; Chattopadhyay G; Klinman DM; Lees A; Mond JJ; Snapper CM
    Cell Immunol; 2004; 232(1-2):64-74. PubMed ID: 15922717
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phosphorothioate-modified TLR9 ligands protect cancer cells against TRAIL-induced apoptosis.
    Chiron D; Pellat-Deceunynck C; Maillasson M; Bataille R; Jego G
    J Immunol; 2009 Oct; 183(7):4371-7. PubMed ID: 19734228
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Specific siRNA downregulated TLR9 and altered cytokine expression pattern in macrophage after CpG DNA stimulation.
    Qiao B; Li B; Yang X; Zhang H; Chu Y; Wang Y; Xiong S
    Cell Mol Immunol; 2005 Apr; 2(2):130-5. PubMed ID: 16191419
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Expression of DNA transcription- and repair-related genes in cisplatin-resistant human ovarian carcinoma cell line COC1/DDP].
    Cao MM; Zhang JR; Wang SM; Hu XG; Hu LJ
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Dec; 25(12):1478-81. PubMed ID: 16354609
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CpG-ODN-based immunotherapy is effective in controlling the growth of metastasized tumor cells.
    Kim HA; Ko HM; Ju HW; Kim KJ; Roh SG; Lee HK; Im SY
    Cancer Lett; 2009 Feb; 274(1):160-4. PubMed ID: 18952369
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO.
    Wingender G; Garbi N; Schumak B; Jüngerkes F; Endl E; von Bubnoff D; Steitz J; Striegler J; Moldenhauer G; Tüting T; Heit A; Huster KM; Takikawa O; Akira S; Busch DH; Wagner H; Hämmerling GJ; Knolle PA; Limmer A
    Eur J Immunol; 2006 Jan; 36(1):12-20. PubMed ID: 16323249
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phosphorothioate modification of the TLR9 ligand CpG ODN inhibits poly(I:C)-induced apoptosis of hepatocellular carcinoma by entry blockade.
    Zhang Y; Lin A; Sui Q; Zhang C; Tian Z; Zhang J
    Cancer Lett; 2014 Dec; 355(1):76-84. PubMed ID: 25224571
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CpG motifs of bacterial DNA exert protective effects in mouse models of IBD by antigen-independent tolerance induction.
    Bleich A; Janus LM; Smoczek A; Westendorf AM; Strauch U; Mähler M; Hedrich HJ; Fichtner-Feigl S; Schölmerich J; Falk W; Hofmann C; Obermeier F
    Gastroenterology; 2009 Jan; 136(1):278-87. PubMed ID: 18952084
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy.
    Mason KA; Ariga H; Neal R; Valdecanas D; Hunter N; Krieg AM; Whisnant JK; Milas L
    Clin Cancer Res; 2005 Jan; 11(1):361-9. PubMed ID: 15671567
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synergy of CpG oligodeoxynucleotide and double-stranded RNA (poly I:C) on nitric oxide induction in chicken peripheral blood monocytes.
    He H; Genovese KJ; Nisbet DJ; Kogut MH
    Mol Immunol; 2007 May; 44(12):3234-42. PubMed ID: 17339052
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antineoplastic effect of immunostimulatory DNA (CpG-ODN) in a murine C57-BL6/MB-49 transitional cell carcinoma model.
    Hegele A; Dalpke A; Barth P; Varga Z; Heeg K; Hofmann R; Olbert P
    Anticancer Res; 2004; 24(4):2225-30. PubMed ID: 15330165
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A threshold level of TLR9 mRNA predicts cellular responsiveness to CpG-ODN in haematological and non-haematological tumour cell lines.
    Assaf A; Esteves H; Curnow SJ; Browning MJ
    Cell Immunol; 2009; 259(1):90-9. PubMed ID: 19573862
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phosphorothioate-modified CpG oligodeoxynucleotide (CpG ODN) induces apoptosis of human hepatocellular carcinoma cells independent of TLR9.
    Zhang Y; Lin A; Zhang C; Tian Z; Zhang J
    Cancer Immunol Immunother; 2014 Apr; 63(4):357-67. PubMed ID: 24452201
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of probiotics, probiotic DNA and the CpG oligodeoxynucleotides on ovalbumin-sensitized Brown-Norway rats via TLR9/NF-κB pathway.
    Zhong Y; Huang J; Tang W; Chen B; Cai W
    FEMS Immunol Med Microbiol; 2012 Oct; 66(1):71-82. PubMed ID: 22612777
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The expression and function of Toll-like receptors 3 and 9 in human colon carcinoma.
    Nojiri K; Sugimoto K; Shiraki K; Tameda M; Inagaki Y; Kusagawa S; Ogura S; Tanaka J; Yoneda M; Yamamoto N; Okano H; Takei Y; Ito M; Kasai C; Inoue H; Takase K
    Oncol Rep; 2013 May; 29(5):1737-43. PubMed ID: 23467704
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Increased sensitivity to chemotherapy induced by CpG-ODN treatment is mediated by microRNA modulation.
    De Cecco L; Berardi M; Sommariva M; Cataldo A; Canevari S; Mezzanzanica D; Iorio MV; Tagliabue E; Balsari A
    PLoS One; 2013; 8(3):e58849. PubMed ID: 23484053
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 17β-Estradiol enhances response of mice spleen B cells elicited by TLR9 agonist.
    Xu Y; Fan H; Li X; Sun L; Hou Y
    Cell Immunol; 2012; 278(1-2):125-35. PubMed ID: 22960279
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combination of cyclophosphamide, rituximab, and intratumoral CpG oligodeoxynucleotide successfully eradicates established B cell lymphoma.
    Betting DJ; Hurvitz SA; Steward KK; Yamada RE; Kafi K; van Rooijen N; Timmerman JM
    J Immunother; 2012 Sep; 35(7):534-43. PubMed ID: 22892450
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of systemic pretreatment with CpG oligodeoxynucleotides on skin wound healing in mice.
    Hergert B; Grambow E; Butschkau A; Vollmar B
    Wound Repair Regen; 2013; 21(5):723-9. PubMed ID: 23927054
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preclinical development of the TLR9 agonist DV281 as an inhaled aerosolized immunotherapeutic for lung cancer: Pharmacological profile in mice, non-human primates, and human primary cells.
    Kell SA; Kachura MA; Renn A; Traquina P; Coffman RL; Campbell JD
    Int Immunopharmacol; 2019 Jan; 66():296-308. PubMed ID: 30502651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.